Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Revenue - OtherRevenue - Rental
Ratios

Maxcyte (MXCT) Depreciation & Amortization (IS) (2021 - 2025)

Historic Depreciation & Amortization (IS) for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to $1.0 million.

  • Maxcyte's Depreciation & Amortization (IS) rose 225.27% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 45.39%. This contributed to the annual value of $4.1 million for FY2024, which is 396.49% up from last year.
  • Latest data reveals that Maxcyte reported Depreciation & Amortization (IS) of $1.0 million as of Q3 2025, which was up 225.27% from $1.1 million recorded in Q2 2025.
  • Maxcyte's 5-year Depreciation & Amortization (IS) high stood at $1.1 million for Q2 2025, and its period low was $311600.0 during Q1 2021.
  • Moreover, its 5-year median value for Depreciation & Amortization (IS) was $977000.0 (2023), whereas its average is $799478.9.
  • As far as peak fluctuations go, Maxcyte's Depreciation & Amortization (IS) soared by 12895.7% in 2022, and later plummeted by 404.52% in 2024.
  • Maxcyte's Depreciation & Amortization (IS) (Quarter) stood at $381600.0 in 2021, then soared by 128.96% to $873700.0 in 2022, then rose by 21.67% to $1.1 million in 2023, then dropped by 4.05% to $1.0 million in 2024, then grew by 2.35% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $1.1 million for Q2 2025, and $1.1 million during Q1 2025.